CJC-1295
Also known as: CJC1295, growth hormone releasing hormone analog
Studies on CJC-1295, a long-acting GHRH analog, in growth hormone axis and body-composition research contexts.
What does the research say about CJC-1295?
CJC-1295 extends GHRH signaling with albumin binding modifications. Published work focuses on GH pulsatility, IGF-1 dynamics, and phase 1/2 metabolic trials rather than approved therapeutics.
Synapse surfaces peer-reviewed research and researcher networks for informational purposes only. This page does not provide medical advice, dosing guidance, or treatment recommendations.
Research feed: CJC-1295
11 indexed papers matched to curated MeSH concepts in the last 90 days.
Research Peptides for Sale: Quality Standards for BPC-157, TB-500, Sermorelin and Epitalon Procurement
Technical review outlines quality verification standards for research peptides, suggesting improved procurement processes.
Can long-acting growth hormone improve adherence in pediatric growth hormone deficiency?
Narrative review summarizes adherence to long-acting growth hormone in children with growth hormone deficiency, suggesting gaps in evidence.
Therapeutic peptides in gerontology: mechanisms and applications for healthy aging
Background: Peptide therapeutics represent an emerging frontier in gerontological medicine, targeting fundamental hallmarks of aging including metabolic dysfunction, telomere attrition, tissue repair impairment, and hormonal decline. Objective: To comprehensively review the mechanisms, clinical applications, evidence base, and safety profiles of therapeutic peptides with demonstrated or potential applications in healthy aging and age-related conditions. Methods: A comprehensive narrative review was conducted through systematic searches of PubMed, Scopus, and regulatory databases (FDA, WADA) from inception through January 2026. Search terms included "peptide therapeutics," "aging," "gerontology," "healthspan," combined with specific peptide names (tirzepatide, epitalon, GHK-Cu, BPC-157, TB-500, Semax, CJC-1295, ipamorelin, bremelanotide). Peer-reviewed articles, clinical trials, regulatory documents, and preclinical studies were evaluated. A total of 20 primary sources were selected based on relevance, methodological quality, and contribution to understanding peptide mechanisms and clinical outcomes in aging populations. Results: Nine peptides were identified spanning diverse aging interventions: metabolic restoration (tirzepatide), telomere biology (epitalon), dermal regeneration (GHK-Cu), tissue repair (BPC-157, TB-500), neuroprotection (Semax), growth hormone modulation (CJC-1295, ipamorelin), and sexual function (bremelanotide). FDA-approved agents demonstrated robust safety profiles from large-scale trials. Non-approved peptides showed promising preclinical and limited clinical evidence but lack long-term safety data and systematic validation. Significant knowledge gaps include optimal dosing regimens, combination therapy effects, and biomarkers for monitoring efficacy. Conclusion: Therapeutic peptides offer mechanistically diverse approaches to multiple aging hallmarks. While FDA-approved agents demonstrate clinical potential, investigational peptides require rigorous validation through well-designed clinical trials to establish safety and efficacy for healthspan extension.
Evidence map and gap analysis of metabolic change in pediatric growth hormone deficiency treated with growth hormone
Evidence map analyzes metabolic changes in growth hormone deficiency, indicating significant gaps for future research.
A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review
Critical review examines peptide drugs' effects in sport, highlighting risks for recreational and professional athletes.
Central Hypothyroidism and Impaired Growth Hormone Secretion Due to Subclinical Cushing's Syndrome: A Case Report
A case report identifies growth hormone reduction in a patient with suppressed adrenocorticotropic hormone, indicating a possible hormonal connection.
Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications
Structured narrative review summarizes injectable peptides' evidence, safety, and antidoping implications in sports medicine.
Growth Hormone Retesting for Idiopathic Isolated Growth Hormone Deficiency During and After Puberty: A Systematic Review
Systematic review evaluates retesting outcomes for growth hormone deficiency in children, suggesting personalized strategies.
Multidisciplinary approach to the treatment of aggressive hormone releasing adenoma: a case report and literature review
Randomized trial examines treatment challenges for aggressive hormone releasing adenoma, suggesting innovative strategies are needed.
The prevalence and etiology of macro-growth hormone (GH)
Study examines macro-growth hormone prevalence in females, revealing rare cases linked to autoantibodies.
Researchers studying CJC-1295
Researcher network data is loading or unavailable for this topic.
Follow CJC-1295 literature with AI-enriched clinical evidence on Synapse.
Search CJC-1295 on SynapsePowered by Synapse — AI-enriched analysis of 600,000+ peer-reviewed papers